Stimwave said this week that it raised more than $50 million from a consortium of unnamed investors for the consumer launch of its Freedom neuromodulation device for treating chronic pain. Pompano Beach, Fla.-based Stimwave said the Freedom stimulator is the sole FDA-approved wireless, micro-sized device cleared for treating neuropathic pain. The device uses a tiny injectable microchip […]
Truffle Capital said this week that the initial closing of its new venture fund, Truffle BioMedTech, brought in $102 million (€85 million) of a hoped-for $240 million. Led by European and Asian institutional and corporate investors and family offices, the fund will look to sniff out “major breakthroughs” at North American and European research centers and […]
Pavmed (NSDQ:PAVM) said today it would cut the cash exercise price of each of its Series W warrants from $2.50 to $2.00 apiece. This is the second price cut that Pavmed has given for its outstanding warrants. Each of the New York-based company’s outstanding warrants were exercisable at $5.00 apiece for one share of common stock […]
Braeburn Pharmaceuticals has raised $110 million in a mezzanine round of financing led by Wellington Capital. Other investors included Avista Capital Partners, RA Capital Management, Deerfield Management and Apple Tree Partners. The Princeton, N.J.-based company said it plans to use the new funds to support the FDA approval process and commercialization of CAM2038, a weekly and […]
N.Y.-based startup Eyenovia updated its regulatory filings to reveal that it plans to offer 2.73 million shares priced between $10 – $12 apiece in its initial public offering. The 7-person company, which is developing a device to deliver small doses of drugs to the eye, is applying to list on the Nasdaq exchange under the symbol, “EYEN”. Get the […]
Metavention said today that it closed a $65 million Series C round with funding from New Enterprise Associates, Sanderling Ventures and others. The medical device maker plans to use the funds to optimize its transcatheter-based metabolic neuromodulation therapy for people with Type II diabetes and prepare it for a Phase II trial in the U.S. Get […]
Denali Therapeutics (NSDQ:DNLI) has landed a strategic partnership with Takeda Pharmaceutical (TYO:4502) to develop and commercialize three of its product candidates for neurodegenerative diseases. The deal includes Denali’s preclinical Alzheimer’s projects, among other undisclosed candidates, which make use of the company’s antibody transport vehicles, or ATVs, to penetrate the blood-brain barrier. Get the full story at our sister […]
Swiss biotech Oculis has raised $21 million in a Series B round backed by investors including Novartis (NYSE:NVS) and Bay City Capital. The company is developing topical drugs for back-of-the-eye diseases, which are normally treated with painful injections directly into the eye. Get the full story at our sister site, Drug Delivery Business News.
Drug-delivery tech developer AMW has landed $30 million from the European Union’s lending institution to help fund the company’s development activities and expand production capacity. The German pharmaceutical company’s newly-acquired funds will specifically support a new R&D facility located in Bavaria. Get the full story at our sister site, Drug Delivery Business News.
Delaware-based Ablative Solutions has raised $4 million as part of a $10 million round, according to regulatory filings. The company is developing the Peregrine System, an infusion catheter that delivers diagnostic and therapeutic agents to the perivascular space surrounding blood vessels. The 510(k)-cleared device includes three microneedles that remain within radiopaque guide tubes prior to drug delivery. After […]
Pear Therapeutics said today that it closed a $50 million Series B round to help commercialize its prescription digital substance abuse therapies. Temasek led the round and was joined by 5AM Ventures, Jazz Venture Partners, Novartis (NYSE:NVS) and others. In September, the company’s reSET therapy became the first prescription digital therapeutic approved by the FDA. One month later, […]